Oncogene 55:717 Moasser Page 12th Author manuscript 6th, April 2011 PMC. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins order Odanacatib B, Pisacane PI, et al. Targeting ligand activated ErbB2 signaling inhibits the growth of tumors in the breast and prostate. Cancer Cell. 2002, two:127 137th RW Akita, MX Sliwkowski. Pr clinical trials with erlotinib. Seminars in Oncology. 2003, 30 Suppl 7:15 24th Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky EK, Hudis C, et al. Open multicenter phase II trial of ZD1839 in sufferers with superior breast cancer. Breast Cancer Res Treat. 2002, 76 S33 N ?? 20 Arnould L, Gelly M, Penault Llorca F, Benoit L, F Bonnetain Migeon C, et al. Trastuzumab-based remedy of HER2-positive surveilance outdated K Entire body surveilance-Dependent cellular Cytotoxicity re t re t mechanism Br J Cancer.
2006, 94:259 267th Austin Cd, AM De Maziere, Pisacane PI, SM van Dijk, MX Sliwkowski Eigenbrot C, et al. Endocytosis and sorting of ErbB2 and also the website of action of trastuzumab and geldanamycin treatments for cancer. Mol Cell Biol 2004, 15:5268 S 5282nd Baasner, MH, Klenner CI-1040 T, Hilgard P, Beckers T. Reversible tumorigenesis M USEN. For conditional expression of HER2 / c erbB2 receptor tyrosine kinase Oncogene. 1996, 13:901 911th Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, et al. Tumor K rpern Inhibitory Antique rpers. Prior to the HER-2/neu receptor induce differentiation of cancer cells from human breast cancer cells Res 1992, 52:2580 2589th Baker AF Dragovich T, Ihle NT, Williams R, Fenoglio Preiser C, Powis stability properties G.
phosphoprotein properties being a biological marker of tumor signaling. Clin Cancer Res 2005, 11:4338 4340th Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, PE Miller, BP Boscoe, et al. Biological and biochemical effects of CP 654,577, a selective erbB2 kinase inhibitor. Cancer Research breast cancer human cell. 2003, 63:4450 4459th Baselga J, J Albanell, Ruiz A, Lluch A, Gascon P, Guillem V, et al. Phase II and tumor pharmacodynamic study of gefitinib in sufferers with advanced breast cancer. J Clin Oncol. 2005, 23:5323 5333rd Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 increased Ht Antitumoraktivit t T of paclitaxel and doxorubicin against HER2 / overexpression of new human breast cancer xenografts. Cancer Res 1998, 58:2825 2831st Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al.
Phase II trial of intravenous S Chentliche SE recombinant monoclonal Body Antique p185HER2 individuals with HER2 / neu-overexpression metastatic breast cancer. J Clin Onc. 1996, 14:737 744th Beerli RR, Wels W, Hynes NE. The intracellular Re expression of ancient Re rpern against warmth Is not that a single ErbB two Transformation. J Biol Chem 1994, 269:23931 23936. Absolutely Belimezi MM, Papanastasiou D, E Merkouri, CN Baxevanis, A. Growth inhibition of breast cancer cell lines overexpressing Mamalaki Her2/neu a novel internalized Constantly human Fab Antique St Consistently Rperfragment is. Cancer Immunol Immunother. 2006, 55:1091 1099th Bianco R, Shin I, Ritter CA, yakes FM, Basso A, Rosen N, et al. PTEN/MMAC1/TEP loss EGF receptor expressed in tumor cells neutralized the anti-tumor effect of tyrosine kinase inhibitors of EGFR. Oncogene. 2003, 22:2812 2822nd Blackwell K, Kaplan EH, Franco SX, Marcom PK, Maleski MJ, Sorenson MS, MS Berger. PHA